Nippon Shinyaku, meanwhile, is weighing next steps after its drug Viltepso didn’t outperform a placebo in a Phase 3 study.
OOpsy. Sofdra has no such worries. Best in class.
Certainly unlike me in grade three that's for sure.
- Forums
- ASX - By Stock
- Ann: Botanix Commercial Day Webinar Presentation
Nippon Shinyaku, meanwhile, is weighing next steps after its...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M |
Open | High | Low | Value | Volume |
37.5¢ | 39.0¢ | 37.0¢ | $1.603M | 4.223M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 378157 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 98000 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 243022 | 0.370 |
2 | 310000 | 0.365 |
11 | 672249 | 0.360 |
13 | 763020 | 0.355 |
26 | 466319 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 65000 | 3 |
0.380 | 110000 | 1 |
0.385 | 138158 | 3 |
0.390 | 716162 | 7 |
0.395 | 520775 | 8 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |